NCT01166178 - Zoledronic Acid in MS-patients With Osteoporosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

OsteoporosisMultiple Sclerosis

Interventions

DRUG

Zoledronic Acid

Zoledronic acid 5 mg once a year via intravenous infusion

DRUG

Placebo

Placebo to zoledronic acid once a year via intravenous infusion

DIETARY_SUPPLEMENT

Calcium and Vitamin D combination

Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day

Trial Locations (15)

Novartis Investigative Site, Bamberg

Novartis Investigative Site, Berlin

Novartis Investigative Site, Bochum

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Kassel

Novartis investigative site, Leipzig

Novartis Investigative Site, Leverkusen

Novartis investigative site, Ludwigshafen

Novartis investigative site, Magdeburg

Novartis investigative site, München

Novartis investigative site, Nümbrecht

Novartis investigative site, Oldenburg

Novartis Investigative Site, Siegen

Novartis investigative site, Stade